MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

NEW YORK, May 22, 2024 -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant...

Related Keywords

United States ,New York ,American ,Terese Hammond ,Nasdaq ,Mink Therapeutics Inc ,American Thoracic Society ,University Of California Los Angeles ,California Los ,Nat Commun ,Risk Factors ,